Get started
IOVANCE BIOTHERAP.DL-,001IOVANCE BIOTHERAP.DL-,001IOVANCE BIOTHERAP.DL-,001

IOVANCE BIOTHERAP.DL-,001

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

2LB chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪2.29 B‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.684EUR
Net income (FY)
‪−402.30 M‬EUR
Revenue (FY)
‪1.08 M‬EUR
Shares float
‪223.62 M‬
Beta (1Y)
3.17

About Iovance Biotherapeutics, Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Frederick G. Vogt
Website
iovance.com
Headquarters
San Carlos
Employees (FY)
557
Founded
2007
FIGI
BBG006WY7QS1
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange IOVANCE BIOTHERAP.DL-,001 stocks are traded under the ticker 2LB.
We've gathered analysts' opinions on IOVANCE BIOTHERAP.DL-,001 future price: according to them, 2LB price has a max estimate of 29.62 EUR and a min estimate of 17.59 EUR. Watch 2LB chart and read a more detailed IOVANCE BIOTHERAP.DL-,001 stock forecast: see what analysts think of IOVANCE BIOTHERAP.DL-,001 and suggest that you do with its stocks.
2LB reached its all-time high on Jan 14, 2021 with the price of 43.456 EUR, and its all-time low was 3.108 EUR and was reached on Oct 19, 2023. View more price dynamics on 2LB chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track IOVANCE BIOTHERAP.DL-,001 financials in yearly and quarterly reports right on TradingView.
IOVANCE BIOTHERAP.DL-,001 is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
2LB earnings for the last quarter are −0.39 EUR per share, whereas the estimation was −0.39 EUR resulting in a 1.02% surprise. The estimated earnings for the next quarter are −0.32 EUR per share. See more details about IOVANCE BIOTHERAP.DL-,001 earnings.
IOVANCE BIOTHERAP.DL-,001 revenue for the last quarter amounts to ‪662.65 K‬ EUR despite the estimated figure of ‪1.88 M‬ EUR. In the next quarter revenue is expected to reach ‪26.95 M‬ EUR.
2LB net income for the last quarter is ‪−104.70 M‬ EUR, while the quarter before that showed ‪−105.44 M‬ EUR of net income which accounts for 0.70% change. Track more IOVANCE BIOTHERAP.DL-,001 financial stats to get the full picture.
No, 2LB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 3, 2024, the company has 557.00 employees. See our rating of the largest employees — is IOVANCE BIOTHERAP.DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IOVANCE BIOTHERAP.DL-,001 EBITDA is ‪−398.60 M‬ EUR, and current EBITDA margin is ‪−35.95 K‬%. See more stats in IOVANCE BIOTHERAP.DL-,001 financial statements.
Like other stocks, 2LB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IOVANCE BIOTHERAP.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.